Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease

NCT05291234 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05291234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05291234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2022
Completion date
November 19, 2025
Enrollment
106 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease (ad)